Nirapamib a PARP inhibitor, is now available for maintenance treatment in all women with advanced epithelial, primary peritoneal or fallopian cancer regardless of BRCA mutation status who have responded to platinum based chemo.
Olaparib (Lynparza) is only approved for women with germline BRCA mutations.
PARP inhibitors work by preventing cancer cells from repairing their DNA damage caused by previous anticancer medications.
Despite FDA approval for front-line therapy after platinum based chemo, the side effects may make the drug intolerable for some women. These include anemia, neutropenia, GI toxicity and fatigue.
To read more about Nirapamib's approval, follow this link.
In October 2012, a dream was realized for two dynamic ovarian cancer survivors: Anne Tonachel and Robin Bray. Their dream was to provide a restorative retreat for other ovarian cancer survivors in the northeast. When the amazing Kennedy family of Camp Kieve and The Kennedy Learning Center provided the retreat space (in honor of a family member with ovarian cancer), this restorative retreat was born.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment